Lung cancer immunotherapy: progress, pitfalls, and promises

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Feb. 21, 2023

Abstract Lung cancer is the primary cause of mortality in United States and around globe. Therapeutic options for lung treatment include surgery, radiation therapy, chemotherapy, targeted drug therapy. Medical management often associated with development resistance leading to relapse. Immunotherapy profoundly altering approach owing its tolerable safety profile, sustained therapeutic response due immunological memory generation, effectiveness across a broad patient population. Different tumor-specific vaccination strategies are gaining ground cancer. Recent advances adoptive cell therapy (CAR T, TCR, TIL), clinical trials on cancer, hurdles discussed this review. patients (without targetable oncogenic driver alteration) reveal significant responses when treated programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockade immunotherapies. Accumulating evidence indicates that loss effective anti-tumor immunity tumor evolution. vaccines combined immune inhibitors (ICI) can achieve better effects. To end, present article encompasses detailed overview recent developments immunotherapeutic landscape targeting small (SCLC) non-small (NSCLC). Additionally, review also explores implication nanomedicine immunotherapy as well combinatorial application traditional along regimens. Finally, ongoing trials, obstacles, future outlook strategy highlighted boost further research field.

Language: Английский

---

Natural killer cells in antitumour adoptive cell immunotherapy

Nature reviews. Cancer, Journal Year: 2022, Volume and Issue: 22(10), P. 557 - 575

Published: July 25, 2022

Language: Английский

---

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion

EBioMedicine, Journal Year: 2022, Volume and Issue: 77, P. 103941 - 103941

Published: March 1, 2022

Language: Английский

---

Exploring treatment options in cancer: Tumor treatment strategies

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: July 17, 2024

Traditional therapeutic approaches such as chemotherapy and radiation therapy have burdened cancer patients with onerous physical psychological challenges. Encouragingly, the landscape of tumor treatment has undergone a comprehensive remarkable transformation. Emerging fervently pursued modalities are small molecule targeted agents, antibody-drug conjugates (ADCs), cell-based therapies, gene therapy. These cutting-edge not only afford personalized precise targeting, but also provide enhanced comfort potential to impede disease progression. Nonetheless, it is acknowledged that these strategies still harbour untapped for further advancement. Gaining understanding merits limitations holds promise offering novel perspectives clinical practice foundational research endeavours. In this review, we discussed different modalities, including drugs, peptide antibody cell therapy, It will detailed explanation each method, addressing their status development, challenges, solutions. The aim assist clinicians researchers in gaining deeper diverse options, enabling them carry out effective advance more efficiently.

Language: Английский

---

Signaling pathways and therapeutic interventions in gastric cancer

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Oct. 8, 2022

Abstract Gastric cancer (GC) ranks fifth in global diagnosis and fourth cancer-related death. Despite tremendous progress therapeutic strategies significant improvements patient survival, the low malignancy stage is relatively asymptomatic many GC cases are diagnosed at advanced stages, which leads to unsatisfactory prognosis high recurrence rates. With recent advances genome analysis, biomarkers have been identified that clinical importance for diagnosis, treatment, prognosis. Modern molecular classifications uncovered vital roles signaling pathways, including EGFR/HER2, p53, PI3K, immune checkpoint cell adhesion molecules, play tumorigenesis, progression, metastasis, responsiveness. These open way more precise diagnoses treatments patients. Nevertheless, relative significance, temporal activation, interaction with risk factors, crosstalk between these pathways not well understood. Here, we review regulatory of potential biomarkers, targets an emphasis on discoveries. Current therapies, signaling-based immunotherapies exploited past decade, development treatment GC, particularly challenges developing precision medications, discussed. provide a direction integration clinical, molecular, genomic profiles improve treatments.

Language: Английский

---

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Journal for ImmunoTherapy of Cancer, Journal Year: 2022, Volume and Issue: 10(12), P. e005755 - e005755

Published: Dec. 1, 2022

Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 patients who progressed ICI and targeted therapy. Herein, we report independent review committee (IRC)-assessed outcomes 153 treated lifileucel large multicenter Phase 2 therapy trial melanoma.Eligible had that where appropriate. Melanoma lesions were resected (resected tumor diameter ≥1.5 cm) shipped to central good manufacturing practice facility for 22-day manufacturing. received non-myeloablative lymphodepletion regimen, single infusion, up six doses high-dose interleukin-2. The primary endpoint was IRC-assessed ORR (Response Evaluation Criteria Solid Tumors V.1.1).The Full Analysis Set consisted lifileucel, including longer-term follow-up the previously reported. median 3.0 lines prior (81.7% both anti-programmed death protein 1 anti-cytotoxic lymphocyte-associated 4) high disease burden at baseline (median target lesion sum diameters (SOD): 97.8 mm; lactate dehydrogenase (LDH) >upper limit normal: 54.2%). 31.4% (95% CI: 24.1% 39.4%), 8 complete responses 40 partial responses. Median duration not reached study 27.6 months, 41.7% maintained ≥18 months. overall survival progression-free 13.9 4.1 respectively. Multivariable analyses adjusted Eastern Cooperative Oncology Group performance status elevated LDH SOD >median independently correlated (p=0.008); normal

Language: Английский

---

Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: June 16, 2022

γδ T-cells directly recognize and kill transformed cells independently of HLA-antigen presentation, which makes them a highly promising effector cell compartment for cancer immunotherapy. Novel T-cell-based immunotherapies, primarily focusing on the two major T-cell subtypes that infiltrate tumors ( i.e. Vδ1 Vδ2), are being developed. The subset is enriched in tissues contains both as well regulatory with tumor-promoting potential. Vδ2 T-cells, contrast, circulation consist large, relatively homogeneous, pro-inflammatory subset. Healthy individuals typically harbor order 50-500 million Vγ9Vδ2 peripheral blood alone (1-10% total CD3 + population), can rapidly expand upon stimulation. receptor senses intracellular phosphorylated metabolites, accumulate result mevalonate pathway dysregulation or pharmaceutical intervention. Early clinical studies investigating therapeutic potential were based either ex vivo expansion adoptive transfer their systemic activation aminobisphosphonates synthetic phosphoantigens, combined low dose IL-2. Immune-related adverse events (irAE) generally \mild, but efficacy these approaches provided overall limited benefit. In recent years, critical advances have renewed excitement Here, we review strategies discuss prospects those currently evaluated patients future therapies might arise from current pre-clinical results.

Language: Английский

---

Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells

Nature Biotechnology, Journal Year: 2022, Volume and Issue: 40(8), P. 1250 - 1258

Published: March 24, 2022

Language: Английский

---

Cell Membrane-Coated Mimics: A Methodological Approach for Fabrication, Characterization for Therapeutic Applications, and Challenges for Clinical Translation

ACS Nano, Journal Year: 2021, Volume and Issue: 15(11), P. 17080 - 17123

Published: Oct. 26, 2021

Cell membrane-coated (CMC) mimics are micro/nanosystems that combine an isolated cell membrane and a template of choice to mimic the functions cell. The design exploits its physicochemical biological properties for therapeutic applications. demonstrate excellent compatibility, enhanced biointerfacing capabilities, physical, chemical, tunability, ability retain cellular properties, immune escape, prolonged circulation time, protect encapsulated drug from degradation active targeting. These ease adapting them personalized clinical medicine have generated significant research interest over past decade. This review presents detailed overview recent advances in development mimics. primary focus is collate discuss components, fabrication methodologies, significance physiochemical characterization techniques validating CMC mimic. We present critical analysis two main components mimics: mapped their use scenarios. In addition, we emphasized on challenges associated with translation. Overall, this up date toolbox researchers can benefit while designing characterizing

Language: Английский

---

The CD70-CD27 axis in oncology: the new kids on the block

Journal of Experimental & Clinical Cancer Research, Journal Year: 2022, Volume and Issue: 41(1)

Published: Jan. 6, 2022

Abstract The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological solid malignancies. Dysregulation of the CD70-CD27 axis within tumor microenvironment is associated with progression immunosuppression. This contrast to physiological conditions, where tightly controlled expression plays a role co-stimulation responses. In malignancies, cancer cells co-express promoting stemness, proliferation survival malignancy. tumors, only present on which can facilitate evasion through microenvironment. discovery these immunosuppressive effects has unfolded novel target field oncology, CD70. this review, we thoroughly discuss current insights into patterns effect (pre)clinical therapeutic strategies.

Language: Английский

---